The tamiflu (oseltamivir phosphate) market is changing as healthcare organizations, particularly in the United States, are increasingly shifting to OTC distribution. As the United States is one of North America's fastest-growing economies, it is anticipated to have the second-highest revenue in the tamiflu (oseltamivir phosphate) market by 2027. As a result, corporations in the United States are cashing in on the OTC switch trend. According to prominent market players, even emerging market companies are striving for the OTC switch and strategic transactions to introduce tamiflu (oseltamivir phosphate) advancements.
